Medical/Pharmaceuticals
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response
and Enable Patient Stratification for Drug Development.
PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed
2025-12-04 01:00
1909
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...
2025-12-03 08:43
4496
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 stu...
2025-12-02 22:10
5853
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. ...
2025-12-02 22:00
3131
L&C Bio's 'Re2O' Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch
– Surging global demand drives rapid adoption across domestic and international medical sectors – SEONGNAM, South Korea, Dec. 2, 2025 /PRNewswire/ -- L&C Bio (KOSDAQ: 290650, Co-CEOsHwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its p...
2025-12-02 22:00
1454
Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health
SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a...
2025-12-02 22:00
4275
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity ...
2025-12-02 22:00
5006
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...
2025-12-02 13:00
2677
United Imaging Broadens Imaging Portfolio and Advances Native AI at RSNA 2025
The company brings a full array of technology to its two booths in Chicago, showcasing another year of increasing R&D and investment. CHICAGO, Dec. 1, 2025 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will showcase a range ...
2025-12-02 00:00
3169
HZICC：Innovation hub: Hangzhou witness new voices and new ambitions
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects toHangzhou. Among this yea...
2025-11-28 21:25
2476
HZICC：Unlocked potential: why global innovators choose Hangzhou
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured let...
2025-11-28 21:19
2912
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
2025-11-28 21:00
3914
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...
2025-11-28 13:00
2080
Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers
NEW YORK, Nov. 27, 2025 /PRNewswire/ -- As the holiday season approaches,
respiratory health becomes a top priority for individuals living with chronic
conditions such as COPD, sleep apnea, or other lung diseases. VARON,
2025-11-28 06:09
2044
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...
2025-11-27 22:00
3444
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...
2025-11-27 10:39
1905
TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation
SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-perfor...
2025-11-27 00:00
2952
Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season
HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...
2025-11-27 00:00
1587
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
4319
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-t...
2025-11-26 14:00
1652
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 296 media titles]
2026-08-04 07:00
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 295 media titles]
2026-08-06 15:10
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 292 media titles]
2026-08-04 14:30
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
[Picked up by 289 media titles]
2026-08-04 06:00
Most Read
Association of Trade and Commerce Reinforces Commitment to Supporting Singapore Enterprises Through Global Growth at The Entrepreneur Singapore 2026
2026-07-31 21:45
21633
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth
2026-07-31 23:12
11228
Oxford International Digital Institute Launches Oxford ELLT Express to Support Time-Sensitive Student Applications
2026-07-31 22:57
10248
